Global Human Immunoglobulin Market Research Report 2022

Due to the COVID-19 pandemic, the global Human Immunoglobulin market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Human Immunoglobulin market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Human Immunoglobulin landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Intramuscular Injection accounting for % of the Human Immunoglobulin global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Disease Prevention segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Human Immunoglobulin include Takeda, CSL, Grifols, Octapharma, Biotest, China National Pharmaceutical Group Corporation, CTBB, Hualan Bio and RASS, etc. In terms of revenue, the global 3 largest players have a % market share of Human Immunoglobulin in 2021.
This report focuses on Human Immunoglobulin volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Human Immunoglobulin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Human Immunoglobulin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Intramuscular Injection
Intravenous Injection
Segment by Application
Disease Prevention
Treatment
Diagnosis
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Takeda
CSL
Grifols
Octapharma
Biotest
China National Pharmaceutical Group Corporation
CTBB
Hualan Bio
RASS
Shanxi Kangbao Biological Product
Shuanglin Bio Pharma
Sichuan Yuanda Shuyang Pharmaceutical